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Integrated genetic and epigenetic analysis deﬁnes
novel molecular subgroups in rhabdomyosarcoma
Masafumi Seki1,*, Riki Nishimura1,*, Kenichi Yoshida2,3, Teppei Shimamura4,5, Yuichi Shiraishi4, Yusuke Sato2,3,
Motohiro Kato1,6,7, Kenichi Chiba4, Hiroko Tanaka8, Noriko Hoshino9, Genta Nagae10, Yusuke Shiozawa2,3,
Yusuke Okuno3,11, Hajime Hosoi12, Yukichi Tanaka13, Hajime Okita14, Mitsuru Miyachi12, Ryota Souzaki15,
Tomoaki Taguchi15, Katsuyoshi Koh7, Ryoji Hanada7, Keisuke Kato16, Yuko Nomura17, Masaharu Akiyama18,
Akira Oka1, Takashi Igarashi1,19, Satoru Miyano4,8, Hiroyuki Aburatani10, Yasuhide Hayashi20,
Seishi Ogawa2,3 & Junko Takita1
Rhabdomyosarcoma (RMS) is the most common soft-tissue sarcoma in childhood. Here we
studied 60 RMSs using whole-exome/-transcriptome sequencing, copy number (CN) and
DNA methylome analyses to unravel the genetic/epigenetic basis of RMS. On the basis of
methylation patterns, RMS is clustered into four distinct subtypes, which exhibits remarkable
correlation with mutation/CN proﬁles, histological phenotypes and clinical behaviours. A1
and A2 subtypes, especially A1, largely correspond to alveolar histology with frequent PAX3/7
fusions and alterations in cell cycle regulators. In contrast, mostly showing embryonal
histology, both E1 and E2 subtypes are characterized by high frequency of CN alterations and/
or allelic imbalances, FGFR4/RAS/AKT pathway mutations and PTEN mutations/methylation
and in E2, also by p53 inactivation. Despite the better prognosis of embryonal RMS, patients
in the E2 are likely to have a poor prognosis. Our results highlight the close relationships of
the methylation status and gene mutations with the biological behaviour in RMS.
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R
habdomyosarcoma (RMS), a highly aggressive soft-tissue
sarcoma, typically affects children, and it is classiﬁed
into two major subtypes having alveolar (ARMS) and
embryonal (ERMS) histologies1,2. ARMS usually carries speciﬁc
chromosomal translocations that result in PAX3– or PAX7–
FOXO1 fusion genes, whereas ERMS commonly harbours loss of
heterozygosity at 11p15.5 and gains of chromosomes 2, 8, and 12
in varying combinations3,4. Despite aggressive multimodal
therapies, the prognosis of high-risk RMS patients has not been
substantially improved, with a 5-year overall survival rate
being o20–30%5, which prompts a need for new therapeutic
strategies targeting molecular pathways that are relevant to the
pathogenesis of RMS. In this point of view, recent sequencing
studies have revealed a number of recurrent mutational targets of
RMS, including multiple components of the FGFR4/RAS/AKT
pathway, FBXW7, CTNNB1 and BCOR6,7. However, the relatively
low number of mutations in RMS (12.3/tumor sample7) suggests
the involvement of other mechanisms, such as epigenetic
alterations, which have not been disclosed in the previous
studies6–8. To address these issues, we conducted an integrated
molecular study in which a cohort of 60 RMSs cases was
investigated for somatic mutations, CN alterations, and DNA
methylomes using whole-exome/targeted deep sequencing,
Single-nucleotide polymorphism (SNP) array-based CN
analysis, and Inﬁnium 450K arrays, respectively. RNA
sequencing was also performed for the selected tumours for
which high-quality RNA was available (that is, RNA integrity
number 46.0). Here we identify novel methylation clusters that
exhibit distinct genetic abnormalities, histological subtypes and
clinical behaviours, suggesting that aberrant DNA methylation
along with genetic alterations is likely to play key roles in the
pathogenesis of RMS.
Results
Sequencing and CN analyses of RMS. We ﬁrst sequenced the
exome of 16 paired tumours/normal samples of which 3 were also
analysed for relapsed (n¼ 2) and metastatic (n¼ 1) samples
(Supplementary Data 1). The mean coverage was 123 , with
which 88% of the target exome sequences were analysed at a
depth of more than 20 (Supplementary Fig. 1). Among
690-candidate somatic changes detected by our pipeline called
Genomon (http://genomon.hgc.jp/exome/en/index.html), 604 in
531 genes (88%) were validated by deep sequencing
(Supplementary Data 2). The mean numbers of mutation in
primary, metastatic, and relapsed tumours were 24.0, 43.3 and
42.0, respectively. Thus, the mutation rate was slightly higher in
relapsed/metastatic tumours than in primary tumours, although
not statistically signiﬁcant (primary versus metastasis, t-test
P¼ 0.20 and primary versus relapsed, P¼ 0.13; Supplementary
Fig. 2). An excessively high number of somatic mutations was
present in one case (RMS_001) in which an MBD4 gene mutation
was implicated in defective DNA repair9 (Supplementary Fig. 2).
As observed in other cancers, mutations were predominated
by C4T/G4A transitions compared with other transitions or
transversions10 (Supplementary Fig. 3).
Among the 531 mutated genes, only 18 were recurrently
mutated (Table 1), which not only included known mutational
targets in RMS, such as TP53, BCOR, KRAS and other genes in the
FGFR4/RAS/AKT pathway, but also involved in previously
unreported genes, including ROBO1 and additional FGFR4/RAS/
AKT pathway genes6–8,11, such as GAB1 and PTEN (Table 1).
Thus, to validate the initial observation in the discovery samples
and investigate the impact of these mutations on the pathogenesis
and clinical outcomes of RMS, we performed follow-up deep
sequencing for 14 putative driver genes in the entire cohort of 60
RMS cases including the 16 discovery cases (Supplementary
Data 3). Overall, 56 mutations were found in the 14 genes (Table 2,
Supplementary Data 4, Supplementary Fig. 4). The most frequently
mutated genes were TP53 (9/60; 15.0%) and FGFR4/RAS/AKT
pathway genes (24/60; 40%), which were predominantly detected
in ERMS tumours7 (Fig. 1, Table 2). Among FGFR4/RAS/AKT
pathway mutations, RAS pathway genes were mutated in 15 cases,
in which all mutations in NRAS/KRAS/HRAS (n¼ 10) and
PTPN11 (n¼ 2) occurred in hot-spot amino acids involved in
gene activation, whereas three of four NF1 mutations were
frameshift indels resulting in premature truncation of the protein.
Five of six FGFR4mutations affected highly conserved amino acids
within the kinase domain of which four were previously reported
activating mutations11, N535K and V550L. Additional four
mutations involved PIK3CA, which have previously been
reported in other cancers, are thought to be activating in
nature12–14. Other commonly mutated genes were BCOR and
ARID1A. All BCOR mutations and four of six ARID1A mutations
were frameshift or nonsense mutations, suggesting the importance
of inactivation of these genes in the pathogenesis of RMS.
A number of genes and pathways were also recurrently affected
by CN alterations and thought to be implicated in deregulated
Table 1 | Recurrent mutations in rhabdomyosarcoma cases
detected by whole-exome sequencing.
Gene Location N Amino-acid change Histology Sample ID
TP53 17p 2 G245S ERMS RMS_011M
C176G NOS RMS_012P
GAB1 4q 2 S614R ARMS RMS_004R
N233I ARMS RMS_006P
KRAS 12p 2 K117N ERMS RMS_014P
A146T ERMS RMS_015P
PTEN 10q 2 G129R ARMS RMS_001P
A120P ERMS RMS_009R
ARID1A 1p 2 G1847fs ARMS RMS_003R
K1007_I1008fs ARMS RMS_011M
BCOR Xp 2 S1243fs ERMS RMS_014P
E712fs Mixed RMS_017P
ROBO1 3p 2 E1113Q ARMS RMS_005P
Y777C ARMS RMS_007P
AKAP9 7q 2 G2652V ARMS RMS_001M
K2673N ERMS RMS_009R
DNAH5 5p 2 S2920I ERMS RMS_011M
R3096Q, D3271N ERMS RMS_008R
FREM2 13q 2 R1515H Mixed RMS_017P
Q1574L ERMS RMS_008R
C15orf2 15q 2 G917A ARMS RMS_003P
V1147L ERMS RMS_009R
KIF21A 12q 2 E766V Mixed RMS_017P
L956P ERMS RMS_009R
NEB 2q 2 E637Q ARMS RMS_001P
D1595Y ARMS RMS_003P
PTPRO 12p 2 R67T ARMS RMS_002R
N644S Mixed RMS_017P
COL5A2 2q 2 G203V ARMS RMS_001P
G756S ARMS RMS_002P
PXDNL 8q 2 T877M ARMS RMS_004R
R1225Q ARMS RMS_016M
NLRC5 16q 2 R341W ARMS RMS_003P
Q1169H ARMS RMS_001P




ARMS, alveolar rhabdomyosarcoma; ERMS, embryonal rhabdomyosarcoma; NOS, not otherwise
speciﬁed.
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Table 2 | Detected mutations in 60 rhabdomyosarcoma cases by targeted deep sequencing.










































24* (40) 16 (46) 7 (32) 1 (100) 0 (0) 0 (0) 3 (16) 21 (51) 6 (55) 9 (82) 3 (17) 2 (20) 4 (40)
FGFR4 5 (8.3) 5 (14) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 5 (12) 0 (0) 4 (36) 0 (0) 0 (0) 1 (10)
PTPN11 2 (3.3) 2 (5.7) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 2 (4.9) 0 (0) 2 (18) 0 (0) 0 (0) 0 (0)
GAB1 3 (5.0) 1 (2.9) 2 (9.1) 0 (0) 0 (0) 0 (0) 1 (5.3) 2 (4.9) 0 (0) 0 (0) 2 (11) 0 (0) 1 (10)
PIK3CA 3 (5.0) 2 (5.7) 1 (4.5) 0 (0) 0 (0) 0 (0) 1 (5.3) 2 (4.9) 0 (0) 2 (18) 0 (0) 0 (0) 1 (10)
PTEN 2 (3.3) 1 (2.9) 1 (4.5) 0 (0) 0 (0) 0 (0) 0 (0) 2 (4.9) 0 (0) 1 (9.1) 1 (5.6) 0 (0) 0 (0)
HRAS 1 (1.7) 0 (0) 1 (4.5) 0 (0) 0 (0) 0 (0) 0 (0) 1 (2.4) 0 (0) 0 (0) 0 (0) 1 (10) 0 (0)
KRAS 2 (3.3) 2 (5.7) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 2 (4.9) 2 (18) 0 (0) 0 (0) 0 (0) 0 (0)
NRAS 7 (12) 5 (14) 2 (9.1) 0 (0) 0 (0) 0 (0) 1 (5.3) 6 (15) 2 (18) 2 (18) 1 (5.6) 0 (0) 2 (20)
NF1 3 (5.0) 2 (5.7) 0 (0) 1 (100) 0 (0) 0 (0) 0 (0) 3 (7.3) 1 (9.1) 2 (18) 0 (0) 0 (0) 0 (0)
TP53 9 (15) 6 (17) 1 (4.5) 0 (0) 1 (100) 1 (100) 1 (5.3) 8 (20) 0 (0) 5 (45) 2 (11) 1 (10) 1 (10)
FBXW7 1 (1.7) 1 (2.9) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (2.4) 0 (0) 1 (9.1) 0 (0) 0 (0) 0 (0)
BCOR 5 (8.3) 4 (11) 0 (0) 1 (100) 0 (0) 0 (0) 1 (5.3) 4 (9.8) 3 (27) 1 (9.1) 1 (5.6) 0 (0) 1 (10)
ARID1A 6 (10) 4 (11) 2 (9.1) 0 (0) 0 (0) 0 (0) 1 (5.3) 5 (12) 0 (0) 3 (27) 1 (5.6) 0 (0) 2 (20)
ROBO1 2 (3.3) 0 (0) 2 (9.1) 0 (0) 0 (0) 0 (0) 2 (11) 0 (0) 0 (0) 0 (0) 1 (5.6) 0 (0) 1 (10)
ARMS, alveolar rhabdomyosarcoma; ERMS, embryonal rhabdomyosarcoma; NOS, RMS not otherwise speciﬁed; U, unknown; FP, fusion positive; FN, fusion negative; NA, not available.
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Figure 1 | Signiﬁcantly altered pathways in rhabdomyosarcoma. The FGFR4/RAS/AKT pathway (a), cell cycle, and p53 signalling (b) are frequently
altered. Genes with genetic alterations are coloured in light orange. The types of alterations and their frequency in the population are indicated on the right
side of each gene. The percentages of cases with alterations including copy-number alterations and/or gene mutations detected in embryonal and alveolar
subgroups are separately indicated on the left side of each gene. PTEN methylation is also indicated below the gene name and coloured in orange.
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FGFR4/RAS/AKT signalling (focal ampliﬁcation of FRS2 at 12q15;
12%) and cell cycle regulation (focal ampliﬁcation of MYCN at
2p24.3, loss of CDKN2A/B at 9p21, TP53 at 17p13.2, and MDM2
at 12q15; Figs 1 and 2, Supplementary Fig. 5). Other genes
displaying signiﬁcant CN alterations included ALK (2p23.2) and
STAT6 (12q13.3) (Supplementary Data 5 and 6). As previously
reported, the ARMS-related fusion genes PAX3/7 (n¼ 6) and
FOXO1 (n¼ 6) were frequently accompanied by local
ampliﬁcations15,16.
Transcriptome analysis of RMS. Fusion transcripts were inves-
tigated by RNA sequencing in eight cases of RMS, including ﬁve
ERMS and three ARMS cases (Supplementary Data 1). In total,
we identiﬁed 22 fusion transcripts, of which three were predicted
to be in-frame, whereas the remaining 19 were out-of-frame
fusions. Expression of fusion transcripts was conﬁrmed by reverse
transcription-PCR (RT–PCR) for 2 in-frame and 10 out-of-frame
fusions (Supplementary Data 7), but no recurrent fusions were
identiﬁed, except for the PAX3–FOXO1 fusion found in two cases
of ARMS. The NSD1–ZNF346 fusion that was previously iden-
tiﬁed in an ERMS cell line6, was found in a case of ERMS.
However, the NSD1–ZNF346 fusion detected in our study was
out-of-frame and thus functional signiﬁcance of this fusion
transcript is still elusive.
Novel clusters identiﬁed by DNA methylation analysis. To
further explore the molecular basis of RMS, we investigated
genome-wide DNA methylation in 53 RMS tumours using
Inﬁnium HumanMethylation450 BeadChip (Illumina). DNA




































































































Figure 2 | Signiﬁcant copy-number (CN) alterations detected in rhabdomyosarcoma. (a) Statistically signiﬁcant CN gains and losses detected by the
GISTIC algorithm are shown in the left and right boxes, respectively. For each q-value peak, the putative gene targets are listed. A dashed line represents the
centromere of each chromosome. Red and blue lines indicate the q-value for gains and losses, respectively. (b–h) Heatmaps of signiﬁcant CN alterations
are shown for gene targets at 1p36.13 (b), 2p24.3 (c), 2q36.1 (d), 12q15 (e), 13q14.1 (f), 9p21.1 (g) and 17p13.1 (h).
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clustering identiﬁed four unique clusters having distinct methy-
lation signatures (Fig. 3a), and the microarray data were validated
by bisulﬁte sequencing for selected probes (n¼ 160;
Supplementary Fig. 6). Remarkably, we found that these clusters
correlated with histological subtypes, genetic abnormalities and
clinical outcomes. Two clusters, E1 and E2, were composed
almost exclusively of ERMS (95.5%; Fig. 3a), whereas all cases of
ARMS were grouped into the two remaining clusters A1 and A2
(Fig. 3a). Accordingly, all tumours positive for PAX3–FOXO1 or
PAX7–FOXO1 fusions were grouped into the A1/A2 clusters,
although the separation between A1 and A2 did not coincide with
the presence or absence of fusions (Fig. 3a). In our analysis, 29
genes were signiﬁcantly hypermethylated in the E1/E2 clusters
compared with the A1/A2 clusters. On the other hand, only 10
genes were signiﬁcantly hypermethylated in the A1/A2 clusters
compared with those in the E1/E2 cluster (Fig. 3b; Supplementary
Fig. 7; Supplementary Data 8). Among these, the largest extent of
promoter methylation was observed in PTEN in the clusters
E1/E2 and GATA4 in the clusters A1/A2. Of note, we found an
extremely high frequency of PTEN hypermethylation in E/E2
tumours (20 of 22; 90.9%), whereas only two of 28 (7.1%) in
A1/A2 tumours showed PTEN hypermethylation (Fig. 3c).
Subsequent quantitative RT–PCR analysis revealed that PTEN
hypermethylation was signiﬁcantly associated with the absence of
PTEN expression, suggesting that epigenetic silencing of PTEN is
a representative mechanism of E1/E2 tumours (P¼ 0.045;
Supplementary Fig. 8). GATA4 encodes a member of the GATA
family of transcription factors17,18 and has been shown to be
methylated in a subset of RMS cases19. However, because GATA4
expression is limited to the heart, testis and ovary, signiﬁcance of
methylation in RMS pathology is still unclear. We also found 23
genes signiﬁcantly hypermethylated in E2 compared with E1 and
25 genes in A1 to A2 (Supplementary Fig. 9, Supplementary Data
9 and 10). Although these ﬁndings should be validated in
independent samples, methylation of these genes could be
potentially used for discriminating these subtypes.
Characteristics of the methylation subgroups in RMS. To
obtain a better understanding of DNA methylation in each sub-
group, we further performed Ingenuity pathway analysis (http://
www.ingenuity.com/) using probe lists of E1/E2 versus A1/A2, E1
versus E2 and A1 versus A2 (Supplementary Data 8–10). How-
ever, relevant cancer-associated pathways in the pathogenesis of
RMS were not detected in the A1/A2 and E1/E2 subgroups
(Supplementary Data 11 and 12). A functional annotation named
‘abnormal morphology of muscle,’ containing DYSF, ELN, OTX2
and TH, was detected as a signiﬁcantly hypermethylated com-
ponent in A1 compared with A2 (P¼ 6.2 10 4; Supplementary
Data 13–16). In addition, the promoter of P4HTM, the family of
prolyl 4-hydroxylases, was signiﬁcantly hypermethylated in E2
compared with E1 (P¼ 0.035; Supplementary Fig. 9). Intrigu-
ingly, P4HTM hypermethylation was also reported in a previous
study regarding DNA promoter methylation in 10 RMS
tumours19. However, the biological signiﬁcance of these genes in
the pathogenesis of RMS is still unclear.
Next, we analysed the genetic and clinical characteristics of
each methylation subgroup. E1 tumours showed a lower mutation
rate (mean, 20.0/sample) than E2 tumours (mean, 45.0/sample),
although not statistically signiﬁcant (P¼ 0.084). Compared with
the A1/A2 clusters, the E1/E2 clusters were characterized by high
frequencies of multiple chromosomal CN changes including gains
of chromosomes 2, 8 or 12 (P¼ 5.2 10 4). In addition, the
mutation frequency of the FGFR4/RAS/AKT pathway was much
higher in the E1/E2 clusters than in the A1/A2 clusters (P¼ 4.6
 10 4), and these mutations were predominantly observed in
the E2 cluster (54.5% in E1 and 81.8% in E2 versus 17.9% in A1/
A2; Fig. 4; Table 2). Among the FGFR4/RAS/AKT pathway
mutations, mutations in FGFR4, PTPTN11 and PIK3CA fre-
quently occurred in E2 compared with E1 (P¼ 1.0 10 3).
Furthermore, E2 tumours had signiﬁcantly frequent TP53
mutations (45.5%) compared with E1 tumours (0%; P¼ 0.035).
In contrast, mutations and CN alterations affecting cell cycle
regulators, such as MYCN, CDK4 and CDKN2A/B, except for
MDM2, were particularly enriched in the A1/A2 clusters
compared with the E1/E2 clusters (P¼ 0.016), suggesting that
these genes may have driver roles in A1/A2 tumours.
Finally, patients in the E2 cluster displayed signiﬁcantly worse
overall survival than those in the E1 cluster, regardless of stage,





































Figure 3 | Hierarchical clustering of DNA methylation proﬁles and
signiﬁcant PTEN hypermethylation in cluster E1/E2. (a) The heatmap
shows the DNA methylation proﬁles of 53 rhabdomyosarcoma (RMS)
tumours based on unsupervised hierarchical clustering. Tumours were
hierarchically clustered into four subgroups: E1, E2, A1 and A2. Clusters E1
and E2 were composed almost exclusively of embryonal RMS (95.5%),
whereas all alveolar RMS were classiﬁed into clusters A1/A2. Red, high
methylation; blue, low methylation. (b) Volcano plot comparing the number
of signiﬁcantly hypermethylated probes between clusters E1/E2 and A1/A2.
Signiﬁcantly hypermethylated probes showing 42-fold change are
coloured in orange (Po1.0 10 8, Wilcoxon’s rank-sum test). Red dots
represent signiﬁcantly hypermethylated probes in the promoter regions of
PTEN in cluster E. (c) Difference in PTEN methylation intensities between
clusters E1/E2 and A1/A2. Signiﬁcantly higher methylation intensities were
observed in cluster E1/E2 than in cluster A1/A2. The P-value was calculated
using the Wilcoxon rank-sum test. b-values represent signiﬁcantly
hypermethylated eight promoter-associated probes (red dots in the
Volcano plot) of PTEN. For the box and whisker plots, the bottom and top of
the box are the ﬁrst and third quartiles, the line inside the box is the median
and the whiskers extend up to 1.5 times the interquartile range.
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age and the site of tumour involvement (P¼ 0.045; Fig. 4b). In
addition, among commonly mutated genes and pathways, only
TP53 mutations but not FGFR4/RAS/AKT pathway mutations
(including FGFR4, PTPN11, PIK3CA and PTEN mutations)
signiﬁcantly affected the overall survival of E1/E2 patients
(P¼ 2.9 10 3). However, the impact of the E1/E2 classiﬁcation
on overall survival was more prominent than that of the TP53
mutations (Supplementary Fig. 10). These results suggest that the
methylation status that deﬁnes the E1/E2 clusters might be a
predictor of overall survival, independent of gene mutations.
Discussion
Our sequencing screen identiﬁed both previously well-recognized
gene mutations including FGFR4/RAS/AKT pathway mutations
and novel recurrently mutated genes, such as PTEN, GAB1 and
ROBO. Most FGFR4/RAS/AKT pathway alterations, excluding
GAB1, were predominantly found in ERMS (Fig. 1), suggesting
that deregulated FGFR4/RAS/AKT signalling plays an important
role in the pathogenesis of ERMS. Because the PTEN missense
mutation affecting G129 has been reported in several cancers20,21
and is thought to abrogate most PTEN activity, the PTEN G129R
mutation detected in RMS should have an oncogenic effect. The
allele frequency of the PTEN A120P mutation was 0.84, and in
accordance with this ﬁnding, the SNP array analysis disclosed
uniparental disomy involving the PTEN locus by which the
mutated allele was duplicated. Thus, the A120P substitution is
likely to be an oncogenic mutation rather than a non-functional
SNP. Although somatic mutations in GAB1 and ROBO1 have
been reported in several cancers, the role of these genes in the
RMS pathogenesis is unknown22–24.
Probably, the most signiﬁcant ﬁnding in the current study
would be the identiﬁcation of the novel methylation clusters,
which tightly correlated with genetic abnormalities, histological
subtypes and clinical behaviours, underscoring the importance of
integrated molecular analyses. Importantly, this ﬁnding revealed
an otherwise unrecognizable subset of ERMS that showed a poor
prognosis (E2 cluster) for which intensiﬁcation or novel
therapeutic approaches need to be considered. We also found
an extremely high frequency of epigenetic silencing of PTEN in
ERMS. PTEN is one of the most frequently mutated tumour
suppressors in human cancers and is also essential for embryonic
development25. PTEN modulates G1 cell cycle progression by
negatively regulating the FGFR4/PI3K/AKT axis. Thus, the
ﬁnding that PTEN methylation/mutation is highly speciﬁc to
and frequent in the E1/E2 tumours indicates that PTEN may
serve as a diagnostic marker to identify those patients for which
inhibition of the FGFR4/PI3K/AKT axis could have a key
therapeutic role. Finally, the biological/genetic basis for these
distinct methylation clusters, nevertheless, is currently unknown
and it should be addressed in future studies. Since our single
cohort in the current study is very limited, to provide an adequate
assessment of molecular subgroups, more large number of
independent cohorts should be evaluated.
Methods
Samples. This study cohort comprised 66 tumours from 60 cases with RMS
(22 ARMS, 35 ERMS, one mixed type, one RMS, not otherwise speciﬁed, and one
unknown histology. Matched normal specimens (mononuclear cells from periph-
eral blood or bone marrow at diagnosis or in remission) were available in 16 cases,
which were subjected to whole-exome sequencing. In three ARMS cases, samples
from both primary and recurrent or metastatic tumours were available, which were
analysed by whole-exome sequencing. Detailed information on subjects and
samples is provided in Supplementary Data 1 and 3. To generate sufﬁcient DNA
templates of tumour and germline DNA in a subset of cases in which enough
samples were not available, whole-genome ampliﬁcation was performed using the
REPLI-g kit (Qiagen). The ampliﬁed DNAs were used in part for targeted deep
sequencing to validate individual candidate mutations detected in whole-exome
sequencing; to analyse all coding sequences of possible candidate genes in the
validation cohort. Written informed consent for research use was obtained from
patients’ parents, and this study was approved by the Human Genome, Gene
Analysis Research Ethics Committee of the University of Tokyo.
Whole-exome sequencing. In 19 samples from 16 cases, whole-exome capture
libraries were constructed from tumour and matched normal DNA using Agilent
SureSelect Human All Exon 50Mb, V4 or V5 (Agilent Technologies) according to
the manufacturer’s protocol. Enriched exome libraries were sequenced with the
Hiseq 2,000 platform (Illumina). For identifying candidates for somatic mutations
from exome-sequencing data, the EBcall (Empirical Bayesian mutation calling)26
algorism was used. This algorism discriminates somatic mutations from sequencing
errors based on an empirical Bayesian method using sequencing data of multiple
non-paired germline samples.
RNA sequencing. In eight tumour samples from our RMS which high-quality
RNA (that is, RNA integrity number 46.0) was available, RNA sequencing was
performed using Hiseq 2,000. RNA sequencing libraries were prepared using the
Truseq RNA Sample Preparation kit (Illumina). Candidates of fusion transcripts
were identiﬁed using Genomon-fusion. All candidates of gene fusion, which
represented more than two paired-reads were subjected to conﬁrm by RT–PCR-
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Figure 4 | Correlations between DNA methylation clusters and additional parameters. (a) Integrated view of DNA methylation clusters combined
with histology, outcome, fusion status, gene alterations and copy-number changes. The horizontal axis represents each tumor. ARMS, alveolar
rhabdomyosarcoma; ERMS, embryonal rhabdomyosarcoma; NOS, not otherwise speciﬁed; Mut, mutation; Met, methylation; CNA, copy-number alteration;
Hetero., heterozygous; Com. Hetero., compound heterozygous mutation; CN, copy number; LOH, loss of heterozygosity; N, NRAS; K, KRAS; H, HRAS;
P, detected in primary sample alone; R, Detected in relapse sample alone; F, PAX3–FOXO1 fusion-positive ERMS. (b) Kaplan–Meier curves of overall survival
for each DNA methylation cluster. The P-value of the log-rank test is shown.
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based Sanger sequencing. The primer sets used for RT–PCR analysis were listed in
Supplementary Data 7.
Validation of putative somatic variants. To validate putative genomic variants
detected in whole-exome sequencing, targeted deep sequencing was performed27.
Regions encompassing possible variations were ampliﬁed with NotI-tagged
primers. Pooled PCR amplicons were digested with NotI, followed by ligation with
T4 DNA ligase. Ligated PCR amplicons were sonicated into fragments of an
average size of 200 bp using a Covaris sonicator. After being enriched and
multiplexed, the prepared libraries were subjected to deep sequencing using
Illumina Hiseq 2,000 or Miseq with a 100-bp or 150-bp pair-end reads option. Both
tumour and germline DNA were examined to conﬁrm somatic variations. Selective
variants of which PCR primers could be constructed by Primer 328,29 were
subjected to deep sequencing for validation. The validated mutations are listed in
Supplementary Data 2.
Evaluation of mutation candidates. For 14 candidate genes, including recurrent
mutated genes in exome sequencing (TP53, BCOR, ARID1A, GAB1, ROBO1, PTEN
and KRAS), and the associated genes (FGFR4, PIK3CA, HRAS, NRAS, PTPN11,
NF1 and FBXW7), PCR-based deep sequencing of the candidate genes was per-
formed in 66 samples using Hiseq 2000 or Miseq (Illumina). NotI-tagged primers
(Supplementary Data 17) were used to generate each PCR amplicon. Selected exons
were sequenced for FGFR4, PIK3CA and PTPN11. Sample preparation, data
processing and variant detection were performed as described above in the
methods section of Validation of putative somatic variants.
DNA methylation analysis. In 53 RMS samples from 50 cases, comprehensive
DNA methylation analysis was performed with the Inﬁnium HumanMethyla-
tion450 BeadChip (Illumina) according to the manufacturer’s protocol. Beta-values
were converted to M-values30, then pcaMethods bioconductor R package was used
to impute incomplete data. M-values were converted to beta-values again and
imputed beta-values were used for further analyse. To determine the DNA
methylation proﬁles, the following steps were adopted to select probes for
unsupervised clustering analysis. We ﬁrst removed probes that were designed for
sequences on the X and Y chromosomes. Second, we selected probes with variance
ranked in the top 1% of the remaining probes. We then performed unsupervised
hierarchical clustering with 4,708 probes, identifying 4 distinct clusters. To detect
methylation status compared with normal skeletal muscles, published data of the
same 450 k platform was used31. Wilcoxon rank-sum test was performed to select
differentially methylated probes. To detect differentially methylated genes for each
sample, multiplicative decomposition model of gene methylation was adopted. Let
xijk be the beta value at probe location j within 1,500 bps of the transcription start
site of gene k for RMS sample i, cjk be the average beta value at the same location of
the same gene for 48 normal skeletal muscle samples, n be the number of samples,
g be the number of genes, and pk be the number of probes within 1,500 bps of
transcription start site of gene k. For each gene k, we consider a following
multiplicative model of the two-way table of gene methylation changes:
xijk ¼ aikbjk þ cjk þ eijk ; ð1Þ
where eijk is an observation error, aik is the methylation pattern depending on
sample i, and bjk is the methylation pattern depending on probe location j,
respectively. The parameters aik, i¼ 1,y,n and bjk, j¼ 1,y,pk are estimated by
Bayesian principal component analysis32. The signs of aik, i¼ 1,y,n are chosen so
that they are proportional to the average beta value of pk locations of gene k. The z-
score to see if aik is signiﬁcantly larger or smaller than those of the normal skeletal
muscles is then calculated by:





where aNk and s
N
k are the average and s.d. of the sample-dependent methylation
patterns for the normal skeletal muscles, respectively.
For a given threshold T, we can declare the methylation status of gene k for
sample i to be an aberration compared with that of normal skeletal muscles if
|zik|4T. Here identifying aberrations can be thought of as a multiple-testing
problem where we are testing the following hypothesis for each gene within each
sample:
H0 i; kð Þ ¼ no aberration of gene k for sample i: ð3Þ
An estimator of the false discovery rate33 for threshold T can be calculated by




k¼1 I zikj j4Tð ÞI H0 i; kð Þis trueð ÞPn
i¼1
Pg
k¼1 I zikj j4Tð Þ
: ð4Þ
The threshold T is then chosen so that dFDRðTÞo0:001.
Quantitative RT–PCR. Quantitative RT–PCR for PTEN was performed in 19
samples from which enough RNA was available. RNA (200 ng) extracted from the
fresh-frozen tumours were subjected to reverse transcription using the SuperScript
VILO MasterMix (Invitrogen) according to the manufacturer’s protocol.
Quantitative mRNA expression levels were measured using the QuantiTect SYBR
Green PCR kit (Qiagen, Tokyo, Japan) with an iCycler iQ real-time PCR detection
system (Bio-Rad). The optional thermal-cycling condition was as follows: 40 cycles
of a two-step PCR (95 C for 15 s, 58 C for 60 s) after the initial denaturation
(95 C for 10min). For the purpose of normalization, relative expression levels
were calculated by dividing the expression level of the respective gene by that of
GAPDH34. Primers used for quantitative RT–PCR are listed in Supplementary
Data 18.
Bisulﬁte conversion and bisulﬁte sequencing of PTEN. To conﬁrm PTEN
methylation, bisulﬁte sequencing using nested primers was performed. Genomic
DNA (500 ng) was bisulﬁte-modiﬁed using the EpiTect Plus DNA Bisulﬁte Kit
(Qiagen) according to the manufacturer’s instructions. Primer sequences for PCR
amplicons are listed in Supplementary Data 18. Complete bisulﬁte modiﬁcation
was conﬁrmed by bisulﬁte sequence analysis of the replicated normal DNA.
Bisulﬁte sequencing for validation of methylation array. To validate the result
of DNA methylation array, targeted bisulﬁte deep sequencing was performed. Five
samples among each cluster were randomly selected for validation. As positive
controls, two samples of replicated normal DNA were also analysed by bisulﬁte
sequencing. Genomic DNA (1,000 ng) was bisulﬁte modiﬁed using the EpiTect
Plus DNA Bisulﬁte Kit (Qiagen) according to the manufacturer’s instructions.
Among extracted 266 probes (E1/E2 versus A1/A2, E1 versus E2 and A1 versus
A2), we selected probes to validate, which recurrently detected in three or more.
Finally, 160 probes were subjected to target deep sequencing. Bisulﬁte PCR was
performed in 22 samples (20 tumours and two controls) with NotI-tagged primes
as described above. For data analysis, the same method of targeted deep sequencing
was used, with modiﬁed mapping to bisulﬁte converted reference genome.
Methylated cytosine was calculated as variant allele frequency. Validated probes
were listed in Supplementary Data 19. The Spearman correlation coefﬁcient was
used to compare beta-values and methylated allele frequencies.
Pathway analysis. Ingenuity pathway analysis (http://www.ingenuity.com/) was
performed for extracted genes listed in Supplementary Data 8–10.
SNP array analysis. DNA extracted from RMS samples was subjected to SNP
array analysis using Affymetrix GeneChip 250K Nsp or CytoScan HD (Affymetrix)
according to the manufacturer’s protocol. Details regarding the use of these
platforms are listed in Supplementary Data 1 and 3. CNAG/AsCNAR software was
used for subsequent informatics analysis for SNP array data, which enables
accurate detection of allelic status without paired normal DNA, even in the
presence of up to 70–80% normal cell contamination35,36. Signiﬁcant focal CN
alterations were identiﬁed using GISTIC 2.037 for 250 k array data. The array data
have been partially published in the previous our paper3.
Analyses of PAX gene fusions. The status of the PAX3/7–FOXO1 fusion gene was
examined by RT–PCR followed by Sanger sequencing in 34 tumours for which
RNA or cDNA was available. The primers and the PCR condition are listed in
Supplementary Data 20.
Statistical analysis. Fisher’s exact test was used to evaluate the differences in
chromosomal CN changes between ARMS and ERMS or the correlation between
CN changes and prognosis in each subgroup. The numbers of mutations or CN
changes were compared by t-test.
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